Inflammatory Diseases
Conditions
Brief summary
The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of ISIS 353512, to evaluate the blood concentration and rate elimination of ISIS 353512 from the blood, and to evaluate the effectiveness of ISIS 353512 in lowering a protein in the blood associated with inflammation.
Detailed description
This will be a Phase 1, double blind, placebo-controlled, dose-escalation study conducted at a single center to 1)evaluate the safety and tolerability of single and multiple doses of ISIS 353512 administered intravenously and subcutaneously, 2)evaluate the pharmacokinetic profile of single and multiple doses of ISIS 353512 administered intravenously and subcutaneously, and 3)evaluate the pharmacodynamics of ISIS 353512 in lowering constitutive levels of c-reactive proteins in healthy volunteers.
Interventions
DRUGISIS 353512
50 mg via 2 hour IV infusion, single dose
Sponsors
Anapharm
Ionis Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Age 18 to 55 years * Male or female although females must be post-menopausal or surgically sterile * In good health * BMI \< 32 kg/m2 * Give written informed consent to participate in the study * hsCRP at Screening ≥ 0.50 mg/L and ≤ 5.0 mg/L (for 2 measurements ≥ 2 weeks apart; with difference between measurements ≤ 2.5 mg/L)(Multiple Dose Subjects only, not including dose-titration cohorts)
Exclusion criteria
* Pregnant women, nursing mothers or women of childbearing potential * Clinically significant abnormalities in medical history or physical examination * Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood pressure \< 90 mm Hg or \> 140 mm Hg, diastolic blood pressure \< 50 mm Hg or \> 90 mm Hg or heat rate \< 50 or \> 100 bpm) at Screening * Clinically significant abnormalities on laboratory examination, other than hsCRP * Clinically significant abnormalities in coagulation parameters * Positive test for HIV, TB (PPD test) or hepatitis B or C at Screening * History of latent or active tuberculosis or exposure to endemic areas within 8 weeks prior to PPD test at Screening * History of positive PPD test or positive PPD test result (≥ 5 mm) indicating possible tuberculosis infection * Fasting triglycerides \> 400 mg/dL at Screening * Malignancy (with the exception of basal or squamous cell carcinoma of the skin if adequately treated and no recurrence for \> 1 year) * Evidence of ongoing chronic inflammatory condition or infection * Any other concurrent condition which, in the opinion of the Investigator, would preclude participation in this study or interfere with compliance * Regular use of alcohol within 6 months prior to Screening (\> 14 units of alcohol per week; 1 unit = 150 mL of wine, 360 mL of beer, or 45 mL of 40% alcohol) * Use of soft drugs (such as marijuana) within 3 months prior to Screening or hard drugs (such as cocaine, phencyclidine \[PCP\] and crack) within 1 year prior to Screening, or positive urine drug screen at Screening * Smoking \> 10 cigarettes per day * Use of an investigational drug or participation in an investigational study involving a small molecule with 30 days prior to dosing or participation in an investigational study involving biologic compounds within 90 days prior to dosing * Regularly taking OTC medications and/or vitamin supplements that may alter CRP, e.g., NSAIDs, aspirin, vitamin E, fish oil, within 14 days prior to Screening * Receiving prescription medications, including hormone replacement therapy, statins, TNF-α inhibitors, or other anti-inflammatory or immunosuppressive drugs within 30 days prior to Screening * Immunization with a live attenuated vaccine one month prior to dosing or planned vaccination during the course of the study * Blood donation of 50 to 499 mL within 30 days of Screening or of \> 499 mL within 60 days of Screening
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the safety and tolerability of single and multiple doses of ISIS 353512 administered intravenously and subcutaneously. | 14 Days post treatment of each cohort |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the pharmacokinetic profile of single and multiple doses of ISIS 353512 administered intravenously and subcutaneously. | 14 Days post treatment of each cohort |
| To evaluate the pharmacodynamics of ISIS 353512 administered intravenously and subcutaneously. | 14 Days post treatment of each cohort |
Countries
Canada
Outcome results
None listed